Johnson &amp; Johnson to Acquire Guidant
505067
Johnson &amp; Johnson said on Wednesday that it will acquire device manufacturer Guidant Corp. for $25.4 billion. Under the terms of the deal announced on Wednesday, each Guidant share will be exchanged for $30.40
173356
Johnson & Johnson will buy Guidant  Corp. for $23.9 billion in cash and stock, giving the  health-care products maker a foothold in the fast-growing  market for implantable devices that regulate heartbeats, J&J  said on Wednesday.
420803
Johnson &amp; Johnson has agreed to buy Guidant Corp. for $25.4 billion in cash and stock, the companies said on Wednesday, giving the healthcare products maker a foothold
5729
Health care products giant Johnson &amp; Johnson&#39;s $25.4 billion acquisition of Guidant Corp. could face a tough review from regulators because of their competition in the coronary stent market, analysts say.
719489
Pfizer Inc. said on Monday it had  reached a definitive agreement to sell its consumer healthcare  business to Johnson &amp; Johnson for &#36;16.6 billion in cash.
6925
Johnson &amp; Johnson (JNJ.N: Quote, Profile, Research) on Thursday said it does not see any significant antitrust roadblocks getting in the way of its $25.4 billion acquisition of medical device maker Guidant Corp.
731068
Johnson & Johnson will acquire the cardiac device manufacturer for $25.4 billion. The acquisition is the largest business deal in J&J's 118-year history
718989
Johnson & Johnson aims to seal a  purchase of Guidant Corp. without immediately jettisoning the  medical device maker's stent operations, sources familiar with  the situation said on Thursday.
336179
LONDON: Johnson &amp; Johnson has agreed to acquire Guidant Corp for US$25.4bil, adding electrical devices for treating heart disease to a line-up of thousands of health products ranging from Band-Aids to cardiac stents.
197805
Johnson &amp; Johnson, the world&#39;s biggest producer of medical devices, is in talks to buy heart defibrillator maker Guidant Corp.
328860
Stocks to watch on Tuesday: JOHNSON &  JOHNSON JNJ.N, GUIDANT CORP. GDT.N
759956
Johnson & Johnson aims to seal a purchase of Guidant Corp. without immediately jettisoning the medical device maker's stent operations, sources familiar with the situation said on Thursday.
39192
Win-win? That could be the case for Ronald W. Dollens if Johnson &amp; Johnson (nyse: JNJ - news - people ) has its way. Dollens is president and chief executive of Guidant (nyse: GDT - news - people ), J&amp;J&#39;s takeover target.
21679
The anticipated merger of Guidant Corp.  and Johnson & Johnson could give an unintended boost to Boston  Scientific Corp. if Guidant's drug-coated stent launch is  delayed, said analysts looking at the implications of a  potential deal.
667631
The prospect of Johnson &amp; Johnson acquiring Guidant, a medical device maker that brought cutting-edge technology to cardiovascular medicine, has fueled whispers for years, gaining intensity when
646222
The anticipated merger of Guidant Corp. and Johnson &amp; Johnson could give an unintended boost to Boston Scientific Corp. if Guidant's drug-coated stent launch is delayed, said analysts looking at the implications of a potential deal.
470326
Johnson &amp; Johnson said late last night it will acquire Guidant for $23.9 billion, a move that will give the big drug maker a bigger share of the explosive market for heart devices.